898 abstracts found.



Results filter

A feasibility randomised controlled trial looking at the effect on lung cancer diagnosis of giving a Chest X-Ray to smokers aged over 60 with new chest symptoms (ELCID) – feasibility and two-month follow-up data

Year:

Session type:

Richard Neal1, Chris Hurt2, Kirsty Roberts2, Trevor Rogers4, Willie Hamilton3, Rhiannon Tudor Edwards1, Seow Tien Yeo1, Angela Tod6, David Parker5, Emma Thomas Jones2, Kerenza Hood2, Hayley Prout2, Annmarie Nelson2, Allan Barham7, Gareth Griffiths2,
1Bangor University, Bangor, UK,2Cardiff University, Cardiff, UK,3Exeter University, Exeter, UK,4Doncaster Royal Infirmary, Doncaster, UK,5Wrexham Maelor Hospital, Wrexham, UK,6Sheffield Hallam University, Sheffield, UK,7Cardiff, Cardiff, UK

Changes in practice for the management of advanced ovarian cancer in a large UK centre

Year:

Session type:

Laura Cossar1, Madhuchanda Chatterjee1, Rosemary Lord1,
1Clatterbridge Cancer Centre, Wirral, UK

Pharmacological inhibition of NRF2 as a novel strategy for overcoming cisplatin resistance in bladder cancer

Year:

Session type:

Richard M. D. Greensmith1, Omar M. S. El-Taji1, Zhi X. Lin3, Ian M. Copple2, Chris E. Goldring2, Syed A. Hussain1,
1Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK,2MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK,3School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

Single institution nurse-led Abiraterone treatment clinic : 20 months experience and data analysis

Year:

Session type:

Norma Sidek1,2, Maureen Hamill2,
1Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK,2Forth Valley Royal Hospital, Lanarkshire, Scotland, UK

Directing the clinical use of ATR inhibitors

Year:

Session type:

Chris Williamson1, Helen Pemberton1, Rachel Brough1, Richard Elliott1, Christopher Lord1, Alan Ashworth1,
1The Institute of Cancer Research, London, UK

The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey: a comparison of UK-based clinicians to clinicians in the EU and worldwide regarding adjuvant chemotherapy (AdjCT) treatment decisions for early stage HR+, HER2- breast cancer (BC) patients 

Year:

Session type:

Daniel Rea1, Matti Aapro2, Juan Enrique Bargallo Rocha3, Michele De Laurentiis4, László Landherr5, Barbro Linderholm6,16, Terry Mamounas7, Christos Markopoulos8, Miguel Martin9, Patrick Neven10, Alexander Petrovsky11, Roman Rouzier12, Vincent Smit13, Christer Svedman14, Christoph Thomssen15,
1University of Birmingham, Birmingham, UK,2Clinic of Genolier, Genolier, Switzerland,3Instituto Nacional de Cancerologia, Mexico City, Mexico,4National Cancer Institute G. Pascale Foundation, Naples, Italy,5Uzsoki Teaching Hospital, Budapest, Hungary,6Sahlgrenska Academy and University Hospital, Gothenburg, Sweden,7Orlando Health, Orlando, USA,8Athens University Medical School, Athens, Greece,9Hospital General Universitario Gregorio Marañón, Madrid, Spain,10UZ Leuven, Leuven, Belgium,11Russian Cancer Research Center, Moscow, Russia,12Institut Curie-Université Versailles-Saint-Quentin, Paris-Saint-Cloud, France,13Leiden University Medical Center, Leiden, The Netherlands,14Genomic Health, Stockholm, Sweden,SaaleMartin-Luther-University Halle-Wittenberg, Halle,16Karolinska University Hospital, Stockholm, Sweden

A Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 in patients with Advanced Malignancies Expressing the Biomarker HR23B

Year:

Session type:

Toby Eyre1, Avinash Gupta1, Nick Coupe1, Ioannis Karydis1, Semira Sheikh3, Graham Collins2, Nick La Thangue3, David Kerr3, Mark Middleton1,
1Early Phase Clinical Trials Unit, The Oxford Cancer Centre, Churchill Hospital, Oxford, UK,2Department of Clinical Haematology, The Oxford Cancer Centre, Churchill Hospital, Oxford, UK,3Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, UK

An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones

Year:

Session type:

Burcu Anil3, Elizabeth Blackburn3, Tim Blackburn1, Sarah Cully1, Junfeng Liu2, Karim Bennaceur2, Catherine Drummond2, Jane Endicott2,3, Bernard Golding1, Roger Griffin1, Karen Haggerty1, Xiaohong Lu2, John Lunec2, Herbie Newell2, Charlotte Reville1, Christiane Riedinger3, Anna Watson1, Yan Zhao2, Ian Hardcastle1, Martin Noble2,3,
1Newcastle Cancer Centre, School of Chemistry, Newcastle University, Newcastle upon Tyne, UK,2Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK,3Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, Oxford, UK

Page 90 of 90« First...25...90